分子病原体和向治疗的瑞克特转换
Nawar Maher1,2, Amir Karami2, Bassam Francis Matti3
1Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and Azienda Ospedaliero-Universitaria di Alessandria, 56121 Alessandria, Italy.
Biomedicines
|February 27, 2026
概括
里希特转换 (RT) 是慢性淋巴细胞白血病 (CLL) 致命演变为扩散性大B细胞淋巴瘤 (DLBCL). 了解其早期起源和免疫抑制微环境是开发这种侵袭性疾病的新疗法的关键.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 里希特转换 (RT) 是慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 (CLL/SLL) 的罕见,激烈的并发症,演变为扩散性大B细胞淋巴瘤 (DLBCL).
- DLBCL-RT表现出快速进展和对常规化疗免疫疗法的耐药性,需要新的治疗策略.
- 克隆相关性是RT的标志,大多数病例来自先前的CLL克隆,导致预后较差.
研究的目的:
- 审查当前对里希特转换病原学的理解,包括克隆进化和遗传驱动因素.
- 探索DLBCL-RT中的免疫抑制瘤微环境及其在免疫逃避中的作用.
- 总结DLBCL-RT的新兴治疗策略,强调个性化和组合方法.
主要方法:
- 综述多原子数据和RT病例的遗传分析.
- 对瘤微环境的分析,包括免疫细胞种群和检查点分子表达.
- 关于新型治疗剂和方法的临床前和临床数据的综合.
主要成果:
- RT通常起源于变化前的亚克隆,代表了早期的进化轨迹,而不是晚期的事件.
- 关键的遗传病变 (例如TP53,CDKN2A/B) 和代谢重新连接 (OXPHOS,mTOR) 驱动转化和攻击性生长.
- RT微环境的特点是免疫抑制细胞 (Tregs,M2巨细胞) 和免疫检查点 (PD-1/PD-L1),促进免疫逃逸.
结论:
- 转基因病原包括早期的克隆进化,特定的遗传变化和高度免疫抑制的微环境.
- 包括向药物,双特异抗体和CAR-T细胞在内的新兴疗法显示出有前途.
- 生物标志物驱动的分层和合理的治疗组合对于改善DLBCL-RT的结果至关重要.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
8.0K
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
3.0K
相关概念视频
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:23Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
02:38Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
02:15M-Cdk Drives Transition Into Mitosis
6.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
01:27Transducer Mechanism: Enzyme-Linked Receptors
4.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.5K